© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Valeant Acquisition of Salix Pharmaceuticals
Posted 27th February 2015

Valeant Acquisition of Salix Pharmaceuticals

NULL

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Valeant Acquisition of Salix Pharmaceuticals
Image

Valeant Acquisition of Salix Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies. 

Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of innovative, new assets. 

“Salix’s market-leading gastrointestinal franchise is an ideal strategic fit for Valeant’s diversified portfolio of specialty products,” said J. Michael Pearson, Valeant’s chairman and chief executive officer. “The growing GI market has attractive fundamentals, and Salix has a portfolio of terrific products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products. With strong brand recognition among specialist GI prescribers, a highly rated specialty sales force, and a significant product and commercial presence across the undertreated and underserved gastrointestinal market, this acquisition offers a compelling opportunity for Valeant to create a strong platform for growth and business development.” 

Thomas W. D’Alonzo, Chairman of the Board and Acting Chief Executive Officer of Salix, stated, “We are pleased to have reached an agreement with Valeant, which is a logical partner and importantly, creates immediate value for our shareholders. Combining Salix’s leading market position in gastroenterology with Valeant’s scale and resources will create a stronger and more diverse business committed to providing better health solutions to health care providers and their patients. We are proud of the accomplishments of our Salix team. Together, we have built our company into the leading gastrointestinal specialty pharmaceutical company, providing solutions for patients and healthcare providers. We look forward to working with the Valeant team to ensure a smooth transition.”

To find out more information about either company, please visit www.valeant.com or www.salix.com.

Categories: M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Norbord’s and Ainsworth’s Merger
M&A
28/05/2015Norbord’s and Ainsworth’s Merger

Norbord's and Ainsworth's Merger

Read Full PostRead - Eye Icon
Acquisition (USD2.5b): Zillow/Trulia
Finance
27/02/2015Acquisition (USD2.5b): Zillow/Trulia

Acquisition International reports on Zillow, Inc.'s acquisition of Trulia, Inc. for $2.5 billion in a stock-for-stock transaction, and formed Zillow Group, Inc.

Read Full PostRead - Eye Icon
Cloud-Based Management Systems Designed to Inspire and Empower
Innovation
07/08/2024Cloud-Based Management Systems Designed to Inspire and Empower

Enabling organisations through its suite of pioneering management systems, IQMS Australasia, offers a highly refreshing approach when it comes to management solutions.

Read Full PostRead - Eye Icon
Bang for Your Buck
Finance
27/06/2017Bang for Your Buck

Stanmore IP is a small, but mighty, trade mark practice who were recently given the Best in Trademark Protection award. Based in the UK, they specialise in helping businesses to select and protect their trade marks in the UK, the EU and globally via a strong n

Read Full PostRead - Eye Icon
Merrill Datasite Advise Fraser’s Acquisition of Malmaison
M&A
30/07/2015Merrill Datasite Advise Fraser’s Acquisition of Malmaison

Merrill Datasite Advise Fraser's Acquisition of Malmaison

Read Full PostRead - Eye Icon
Centum Acquisition of a Controlling Stake in K-Rep Bank
M&A
01/02/2015Centum Acquisition of a Controlling Stake in K-Rep Bank

Centum, the East African investment firm, announced the acquisition of a controlling stake in Kenyan bank K-REP Bank Limited.

Read Full PostRead - Eye Icon
US Deal Making Smashes Records
Finance
04/06/2015US Deal Making Smashes Records

During May US deal making hit an all time monthly high.

Read Full PostRead - Eye Icon
Best Classical Music Promotions Company – UK
Finance
01/07/2016Best Classical Music Promotions Company – UK

From Sweden Productions are a London-based production company specialising in production management and promotions of large-scale high profile concerts, festivals and events with a Swedish connection.

Read Full PostRead - Eye Icon
Eight Common Tech Business Terms That Are Often Misunderstood
Innovation
12/05/2023Eight Common Tech Business Terms That Are Often Misunderstood

Business leaders within UK SMEs have been told the eight most commonly misunderstood technological terms to avoid misinformation negatively impacting performance.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow